Cervical cancer subtypes harbouring integrated and/or episomal HPV16 portray distinct molecular phenotypes based on transcriptome profiling of mRNAs and miRNAs by Mandal P et al.
Mandal et al. Cell Death Discovery            (2019) 5:81 
https://doi.org/10.1038/s41420-019-0154-x Cell Death Discovery 
ART ICLE Open Ac ce s s
Cervical cancer subtypes harbouring
integrated and/or episomal HPV16 portray
distinct molecular phenotypes based
on transcriptome profiling of mRNAs
and miRNAs
Paramita Mandal1,6, Sweta Sharma Saha1,7, Shrinka Sen1,8, Amrapali Bhattacharya1, Nitai P. Bhattacharya2,
Sudha Bucha2, Mithun Sinha2,9, Rahul Roy Chowdhury3, Nidhu Ranjan Mondal3, Biman Chakravarty3,
Tanmay Chatterjee3, Sudipta Roy4, Ansuman Chattapadhyay5 and Sharmila Sengupta1
Abstract
Heterogeneity in cervical cancers (CaCx) in terms of HPV16 physical status prompted us to investigate the mRNA and
miRNA signatures among the different categories of CaCx samples. We performed microarray-based mRNA expression
profiling and quantitative real-time PCR-based expression analysis of some prioritised miRNAs implicated in cancer-
related pathways among various categories of cervical samples. Such samples included HPV16-positive CaCx cases that
harboured either purely integrated HPV16 genomes (integrated) and those that harboured episomal viral genomes,
either pure or concomitant with integrated viral genomes (episomal), which were compared with normal cervical
samples that were either HPV negative or positive for HPV16. The mRNA expression profile differed characteristically
between integrated and episomal CaCx cases for enriched biological pathways. miRNA expression profiles also
differed among CaCx cases compared with controls (upregulation—miR-21, miR-16, miR-205, miR-323;
downregulation—miR-143, miR-196b, miR-203, miR-34a; progressive upregulation—miR-21 and progressive
downregulation—miR-143, miR-34a, miR-196b and miR-203) in the order of HPV-negative controls, HPV16-positive
non-malignant samples and HPV16-positive CaCx cases. miR-200a was upregulated in HPV16-positive cervical tissues
irrespective of histopathological status. Expression of majority of the predicted target genes was negatively correlated
with their corresponding miRNAs, irrespective of the CaCx subtypes. E7 mRNA expression correlated positively with
miR-323 expression among episomal cases and miR-203, among integrated cases. miR-181c expression was
downregulated only among the episomal CaCx cases and negatively correlated with protein coding transcript of the
proliferative target gene, CKS1B of the significantly enriched “G2/M DNA Damage Checkpoint Regulation” pathway
among CaCx cases. Thus, the two CaCx subtypes are distinct entities at the molecular level, which could be
differentially targeted for therapy. In fact, availability of a small molecule inhibitor of CKS1B, suggests that drugging
CKS1B could be a potential avenue of treating the large majority of CaCx cases harbouring episomal HPV16.
Introduction
Cervical cancer (CaCx) appears to be the most common
malignancy in Indian women, characterised by high
incidence and mortality rates that are attributable to late
detection and lack of access to affordable health care.
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Oncogenic human papillomavirus (HPV) infections are
the major aetiological factors, with a predominance of
HPV16 that accounts for over 50% of such cancers1. Viral
oncoprotein E6 is known to interact with the tumour
suppressor p53 and E7, with the PDZ domain of cellular
proteins and Rb, thereby facilitating neoplastic progres-
sion through loss of cellular homoeostasis2. Loss of E2
repressor activity, as a consequence of integration of the
virus into the host genome, is known to impart pro-
liferative advantage to the host cells3. Besides this, our
earlier studies have highlighted mechanisms that act to
block the E2-mediated repression of the P97 promoter4 in
CaCx cases harbouring episomal HPV16 and revealed that
such cancers harbour higher viral load and E7 expression
in contrast to the ones that portray integrated HPV16.
Cervical carcinogenesis, under the impact of oncogenic
HPV infections, could be influenced by several epigenetic
mechanisms like DNA methylation, histone modifica-
tions, by microRNAs, etc., through perturbations of
gene expression profiles. In this communication, we
chose to focus on the expression of host mRNAs and
miRNAs in various categories of cervical samples
spanning the discrete stages of CaCx development.
These small non-coding RNAs, through recognition of
sequence-complementary target elements, can either
translationally suppress or catalytically degrade both cel-
lular and viral RNAs5,6. Both DNA and RNA viruses have
evolved mechanisms to degrade, boost, or hijack cellular
miRNAs to benefit the viral life cycle7. Therefore, a
glimpse of the deregulated expression of mRNAs and
miRNAs in CaCx cases might offer some insights into the
mechanisms of CaCx pathogenesis among the two sub-
types that bear integrated HPV16 and episomal HPV16 in
presence or absence of integration, subsequently referred
to as integrated and episomal CaCx cases, respectively.
About 50% of the known human miRNAs8 are located
at cancer-associated regions9 of the genome and a num-
ber of miRNAs are located close to HPV integration sites.
Host miRNAs are also capable of influencing viral life
cycles, viral tropism, and the pathogenesis of viral dis-
eases5. Therefore, miRNA-mediated epigenetic regulation
of gene expression might play a role in virus associated
cancers, like CaCx.
Some studies have strongly suggested that miRNA
profiling is more robust than mRNA profiling in deter-
mining the heterogeneity among cancers10. The studies
on CaCx11,12 have also demonstrated the association of
miRNA deregulation with tumour heterogeneity. The
heterogeneity among CaCx in terms of physical status of
HPV16 genomes by our group13, prompted us to explore
the mRNA and miRNA signatures among the different
categories of CaCx samples.
Hence, we tested the hypothesis that CaCx cases with
integrated and episomal HPV16 genomes differ with
respect to such gene expression profiles and corre-
sponding enriched pathways. We further explored whe-
ther a prioritised set of miRNAs, implicated in various
cancer-related pathways, show altered expression and
play a role in CaCx pathogenesis under the impact
of HPV16 infection. Subsequently, we determined
whether the miRNAs showing altered expression in
CaCx cases, correlate with (i) the physical status of
HPV16 genomes (episomal and integrated), (ii) expression
of the oncoprotein E7, (iii) the expression of cellular
target genes of specific biological pathways and checked
the relationship, if any, between such target genes and
viral oncoprotein E7.
Results
Microarray-based gene expression profiling reveals
characteristic differences among CaCx cases harbouring
episomal and integrated HPV16 genomes
To identify the differences between CaCx cases har-
bouring episomal and integrated HPV16 genomes, we
first attempted to identify global gene expression level
changes between the two categories of CaCx cases. Our
microarray-based analysis revealed that 334 genes were
differentially upregulated and 253 were differentially
downregulated among episomal CaCx cases, whereas
1373 genes were differentially upregulated and 1240 were
differentially downregulated among integrated CaCx
cases, compared with the HPV-negative control samples
(Figure S1). Ingenuity pathway analysis (IPA) revealed
that biological processes such as cell proliferation, retro-
viridae infection, and viral Infections were the most sig-
nificantly enriched among the episomal CaCx cases. On
the other hand, biological processes such as transcription,
proliferation of tumour cells, and protein metabolism
were most significantly enriched among integrated CaCx
cases (Table S1). IPA also revealed that role of CTLA4-
signalling in cytotoxic T lymphocytes and T-cell receptor
signalling were the top significantly altered pathways
among the episomal CaCx cases, whereas EIF2 signalling,
regulation of eIF4 and p70S6K signalling, mitochondrial
dysfunction, and mTOR signalling were the top sig-
nificantly altered pathways among integrated CaCx cases
(Table S2). Moreover, the upstream regulators involved
in alteration of gene expression, differed distinctly among
the two CaCx subtypes (Table S3). Such observations
further strengthen our hypothesis that the episomal and
integrated CaCx cases represent two distinct molecular
subtypes.
miRNAs reveal altered expression among CaCx cases
compared with HPV-negative controls and HPV16-positive
non-malignant samples
The 34 miRNAs selected for this study belonged to
eight different categories by function, as depicted in
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Table S4. Of these, nine miRNAs revealed significant
alterations in expression (p value < 0.05) among CaCx
cases compared with HPV-negative controls, as well as
HPV16-positive non-malignant samples as depicted in
Table 1. Among these, four miRNAs (miR-21, miR-16,
miR-205, and miR-323) were significantly overexpressed,
while significant decreased expression was recorded in
case of four miRNAs (miR-143, miR-196b, miR-203, and
miR-34a). miR-200a, however, showed a statistically sig-
nificant increased expression by 37.53-fold, among CaCx
cases compared with HPV-negative controls but not when
compared with HPV16-positive non-malignant samples.
The expression status of all the altered miRNAs are
depicted in Table 1, Figure S2, Fig. 1, Fig. 2 and Fig. 3.
Likewise, seven miRNAs revealed significant alterations
in expression among HPV16-positive non-malignant
samples, compared with HPV-negative controls. Of these,
two miRNAs (miR-21, miR-200a) revealed significant
increased expression and five miRNAs (miR-143, miR-16,
miR-196b, miR-203, and miR-34a) showed significantly
decreased expression. The expression status of all such
altered miRNAs among the HPV16-positive non-malig-
nant sample group is depicted in Table S5, Figure S2,
Fig. 1, Fig. 2, and Fig. 3.
Progressive increase of miR-21 expression and pro-
gressively decreased expression of miR-143, miR-34a,
miR-196b, and miR-203 was recorded with increase in
severity of cervical status through HPV-negative control
samples, HPV16-positive non-malignant samples and
CaCx cases. Such trends were found to be statistically
significant (p < 0.001). On the contrary, miR-16 revealed
a deviation of the trend with decreased expression
among HPV16-positive non-malignant samples, followed
by increased expression among CaCx cases compared
with HPV-negative controls, as depicted in Figure S3.
Such observations are suggestive of the fact that miRNA
deregulations could potentially serve as risk markers of
CaCx development.
Lack of profound impact of physical status of HPV16
genome (episomal and integrated) on expression of
majority of miRNAs in CaCx cases, excepting for miR-181c
In view of the biological relevance of episomal HPV16
among CaCx cases13, expression data of all 34 miRNAs
considered in this study was further analysed to determine
whether they showed differentially altered expression
among the CaCx cases with episomal and integrated
HPV16, when compared with HPV-negative controls and
HPV16-positive non-malignant samples. The sole miRNA
that revealed significantly altered expression only among
episomal CaCx cases was miR-181c, as depicted in Fig. 4.
miR-181c expression was significantly increased in such
cases (fold change=−2.34-fold, p < 0.001), compared
with both HPV-negative and HPV16-positive control
samples (fold change=−15.89 fold; p < 0.001). Similar
analysis considering CaCx cases with integrated HPV16,
failed to show differential expression of miR-181c among
such CaCx cases. Thus, HPV16 physical status within
CaCx cases failed to portray any profound effect on
majority of the miRNAs as depicted in Table 1.
HPV16 E7 mRNA expression levels activate expression of
miR-323 resulting in upregulation among CaCx cases
Based on our clinical sample data we identified that only
two miRNAs (miR-203 and miR-323) were significantly
and positively correlated with E7 mRNA expression,
among the CaCx cases. Interestingly, the correlation
between E7 and miR-323 (Fig. 5) was obvious among
CaCx cases harbouring episomal HPV16, whereas the
correlation between E7 and miR-203 (Figure S4) was
evident among CaCx cases with integrated HPV16. As the
correlation between miR-203 and E7 has already been
documented in earlier studies14, we used an in vitro
approach to confirm the correlation between miR-323
expression and E7 expression in CaCx cases.
We transfected the HPV-negative CaCx cell line, C33A
with HPV16 E7 cloned into mammalian expression vector
pcDNA3.1 (+), as explained in our previous study15.
This resulted in a significant increase in miR-323
expression (8.17-fold; p= 0.032) concomitant with
HPV16 E7 expression (Fig. 6) in such cells. We also
determined miR-323 expression in HPV16-positive CaCx
cell lines, SiHa, and Caski. Expression of miR-323 was
found to be higher among SiHa cells (2.82-fold; p= 0.016)
that portray relatively higher E7 expression15, as com-
pared WITH Caski cells (Fig. 6). Thus, both the obser-
vations confirmed that E7 could probably activate miR-
323 expression in CaCx cases.
Target genes of majority of miRNAs that differ in
expression between CaCx cases harbouring episomal and
integrated HPV16, also portrayed similar expression level
difference between such cases
miRNAs are known to target multiple transcripts reg-
ulating important cellular processes such as cell pro-
liferation, apoptosis, cellular metastasis, and many more16.
To check the impact of deregulated expression of the
nine significantly altered miRNAs including miR-181c, on
their target genes, we identified the expression profiles
of the predicted targets from the microarray-based gene
expression analysis (Table S6). We selected the target
genes of the above mentioned 10 miRNAs, considering
only those targets that portrayed ≥ or ≤ 2 fold change in
expression as compared with the controls. Majority of
such target genes of the corresponding miRNAs seemed
to be experimentally non-validated, as per the databases
considered for target identification as detailed under the
“Methods” section. For miR-181c, only the expression
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status of target genes in case of episomal CaCx cases were
considered for expression changes, as this miRNA was
differentially expressed, compared with controls, only
among the episomal cases but remained unaltered in
expression among the HPV16-integrated CaCx cases.
Overexpression of miR-181c target gene, CKS1B, among
episomal CaCx cases
According to microarray-based gene expression analy-
sis, 44 miR-181c target genes showed differential
expression at more than equal to twofolds among the
episomal CaCx cases. These genes were also found to be
overexpressed among the episomal CaCx cases compared
with integrated CaCx cases (Table S6). Out of these 44
differentially overexpressed genes, CKS1B was the only
gene that was captured in a significantly enriched pathway
among CaCx cases, upon employing IPA (Table S2).
The microarray-based gene expression profile result of
CKS1B is depicted in Table S7. Real-time quantitative
PCR-based validation of the expression of CKS1B on a
larger set of cervical samples, revealed differentially
increased expression of CKS1B by 21.16-fold (p < 0.001)
among CaCx cases (episomal HPV16; n= 43) compared
with HPV16-positive non-malignant samples (n= 25)
and by 18.5-fold (p < 0.001) in comparison with HPV-
negative controls (n= 25), as depicted in Figure S5. CaCx
cases with integrated HPV16 failed to show significant
alteration of the expression of this gene, compared with
HPV16-positive non-malignant samples and HPV-
negative controls.
Fig. 1 Box plots representing distribution of upregulated miRNA expressions (miR-21, miR-200a, and miR-16, normalised with
endogenous control RNU6b and miR-127) among different categories of cervical samples. Lower ΔCT means higher expression. A= HPV-
negative control samples (n= 25), B= HPV16-positive non-malignant samples (n= 25), C= HPV16-positive episomal CaCx cases (n= 43),
D= HPV16-positive integrated CaCx cases (n= 19)
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The expression of CKS1B was inversely and significantly
correlated with miR-181c expression (p= 0.03) based on
pair-wise correlation analysis of various categories of
cervical samples, as depicted in Fig. 4. The episomal CaCx
cases appeared to cluster separately, whereas the inte-
grated CaCx cases clustered together with HPV16-
positive non-malignant samples and HPV-negative con-
trols. Such analysis further confirmed that CKS1B was
differentially overexpressed among episomal CaCx cases
possibly as a consequence of differentially decreased
expression of miR-181c among such cases. On the other
hand, CKS1B is transcriptionally regulated by MYCN,
which has been predicted to be inhibited among the CaCx
cases harbouring integrated HPV16, based on IPA in this
study (Table S2). This observation was therefore, in
concordance with the fact that CKS1B failed to show any
alteration in expression, compared with controls, in such
CaCx subtypes (Table S5). Such observations also reflect
that the two CaCx subtypes with episomal and integrated
HPV16 are distinct, molecularly.
miR-181c target gene, CKS1B, correlates negatively with
HPV16 E7 expression among the HPV16-integrated CaCx
cases
In an earlier study13, we recorded that the two cate-
gories of CaCx cases differ with respect to levels of viral
oncogene E7 expression. Hence, it became necessary to
explore if the viral oncogene expression had any influence
on the expression of the cellular gene, CKS1B, which is
targeted by miR-181c. Among all the CaCx cases, irre-
spective of the viral physical status and among the epi-
somal CaCx cases, no significant correlation was recorded
between the expression of these cellular genes and viral
oncogene E7. But strikingly, only among integrated CaCx
Fig. 2 Box plots representing distribution of upregulated and downregulated miRNA expressions (miR-205, miR-323, and miR-143,
normalised with endogenous control RNU6b and miR-127) among different categories of cervical samples. Lower ΔCT means higher
expression. A= HPV-negative control samples (n= 25), B= HPV16-positive non-malignant samples (n= 25), C= HPV16-positive episomal CaCx cases
(n= 43), D= HPV16-positive integrated CaCx cases (n= 19)
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cases, a strong negative correlation was identified between
E7 and CKS1B expression (R2= 0.516; p= 0.03) as shown
in Fig. 7.
Discussion
Global gene expression profiling has been used widely
to identify genes that are aberrantly expressed in cervical
tumours as compared with normal cervix17,18, and19.
Considering our earlier study depicting the relevance of
differences between CaCx cases harbouring episomal and
integrated viral genomes13, in the current study, we chose
to identify differentially expressed host genes and relevant
pathways for CaCx pathogenesis in general or specifically
distinct among episomal and integrated CaCx cases.
Besides confirming this, the most important pathways
identified for CaCx pathogenesis, irrespective of HPV
physical status were the cell cycle regulatory pathways
such as “Cell Cycle: G2/M DNA Damage Checkpoint
Regulation”, “Cell Cycle Control of Chromosomal Repli-
cation, Mitotic Roles of Polo-Like Kinase”, and “Role of
BRCA1 in DNA Damage Response”. Altered expression
of proteins belonging to these pathways exert direct
influence on the efficacy of antitumor agents as well as
tumour outcomes20–23. Therefore, a clinical correlation
of genes captured in the enriched pathways would help
in determining the translational efficacy of the findings
recorded in this study.
The most significant pathways identified in case of
episomal CaCx cases was “CTLA4 signalling in cytotoxic
T lymphocytes” and “T-cell receptor signalling”, portray-
ing overexpression of most of the genes captured in such
pathways. Such exclusively enriched pathways could
probably be attributable to higher viral load and E7
expression, in such cancers harbouring episomal HPV1613
and reflective of the role of the tumour immune micro-
environment or the role of tumour infiltrating
Fig. 3 Box plots representing distribution of downregulated miRNA expressions (miR-34a, miR-196b, and miR-203, normalised with
endogenous control RNU6b and miR-127) among different categories of cervical samples. Lower ΔCT means higher expression. A= HPV-
negative control samples (n= 25), B= HPV16-positive non-malignant samples (n= 25), C= HPV16-positive episomal CaCx cases (n= 43), D=
HPV16-positive integrated CaCx cases (n= 19)
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lymphocytes in such CaCx subtypes. Therefore, genes of
such pathways could potentially serve as targets for
combating such cancers, efficiently. On the other hand,
the most significantly enriched pathways in CaCx cases
harbouring integrated HPV16 were signalling pathways
such as “eIF2 Signalling”, “Regulation of eIF4 and p70S6K
Signalling”, and “mTOR Signalling”, together with
“Mitochondrial Dysfunction” pathway. Such signalling
pathways associate with processes like oxidative stress
and DNA repair, autophagy, and cell migration. These
observations could be suggestive of the potential role of
the host virus fusion proteins that are common among
HPV16-integrated CaCx cases, where heterogeneous
levels of viral oncoprotein E7 do not correlate with viral
copy numbers13.
Among the miRNAs with altered expression levels
recorded in our study, majority followed expression pat-
terns that have already been recorded in case of CaCx
cases, with the exception of miR-200a and miR-181c. The
overexpression of miR-200a revealed a pattern that dif-
fered from the other miRNAs analysed, suggesting that
this miRNA could be associated with HPV16 positivity.
A recent study24 identified overexpression of miR-200a
in HPV induced CaCx and tonsillar cancers, which seems
to be consistent with our observation. Another recent
study by the Cancer Genome Atlas Research Net-
work, 201725 identified that expression of miR-200 family
was negatively correlated with those of the
epithelial–mesenchymal transition-related transcription
factors. Overexpression of miR-200a in pancreatic
cancers26 and ovarian cancers27 have been recorded and
attributed as contributing to the epithelial phenotype
and cell proliferation maintaining the tumour bulk,
respectively. Although such phenomenon might explain
our findings and be prognostically relevant, it could also
be worthwhile to hypothesise that this miRNA may
serve as an early marker of HPV16 infection, specifically
for singling out HPV16-positive women who might be
at heightened risk for CaCx development.
Unlike miR-200a, miR-181c showed differentially
downregulated expression, exclusively among episomal
CaCx cases but not among integrated CaCx cases. miR-
181c has already been reported as a p53-miR, which tar-
gets a number of components of the miRNA processing
complex28. A study29 suggested that expression level of
miR-181c in the serum can be used as a biomarker for
therapeutic efficacy in cervical cancers. Thus, miR-181c
expression status could potentially serve as a novel risk
marker for episomal CaCx cases and calls for functional
characterisation of the role of this miRNA in episomal
CaCx pathogenesis. We tested this possibility by focussing
our attention on the miR-181c target gene, CKS1B, which
belonged to the significantly enriched pathway in cervical
cancers. We identified that CKS1B was differentially
overexpressed only among episomal CaCx cases, whose
expression was significantly and inversely correlated with
miR-181c expression in such CaCx subtype.
Enhanced expression of CKS1B in a number of cancers
such as myeloma, breast cancer, lymphoma, renal carci-
noma, ovarian cancer, salivary, and oesophageal cancers
Fig. 4 Expression status of miR-181c and its correlation with CKS1B expression. a Box plots representing distribution of miR-181c expression
among different categories of cervical samples. b Linear regression analysis of the correlation between CKS1B mRNA expression and miR-181c
expression in all cervical samples (p= 0.03) Lower ΔCT means higher expression. A= HPV-negative control samples (n= 25), B= HPV16-positive non-
malignant samples (n= 25), C= HPV16-positive episomal CaCx cases (n= 43), D= HPV16-positive integrated CaCx cases (n= 19)
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etc. has been associated with poor prognosis. This has
been attributed to amplification of CKS1B gene leading to
lymph node metastases30. Besides influencing cell growth
and survival through regulation of p27Kip1, silencing of
CKS1B is also known to induce cell death and inhibit
growth of tumour cells through mechanisms that are
independent of p27Kip1and SKP231,32. Taken together,
our study highlights a novel mechanism of CKS1B over-
expression in HPV16 episomal CaCx subtypes, which
could be attributable to loss of epigenetic regulation of
CKS1B by miR-181c, which is downregulated in such
CaCx subtypes. Thus, this could serve as one of the
mechanisms of proliferation activation in this CaCx sub-
type that could be of translational relevance.
There exist at least two transcript variants of CKS1B
gene and it appears that only transcript variant 1 encodes
the protein33. In our study, we employed primers designed
to capture the expression of this coding variant of CKS1B.
Hence, availability of a small molecule inhibitor of CKS1B,
fluoxetine, which is used as an antidepressant in clinics34,
suggests that drugging CKS1B could be a potential avenue
of treating such CaCx subtypes harbouring episomal
HPV16, as opposed to those harbouring purely integrated
HPV16 and this could be subject to clinical trials.
Our previous study also demonstrated that there exists
heterogeneity among integrated CaCx cases, based on
viral load and E7 expression level13. The negative corre-
lation between E7 expression and expression of CKS1B
among such cases potentially suggests the complementary
role of viral and host proteins, in the pathogenesis of such
CaCx cases harbouring integrated HPV16 irrespective
of miR-181c (Fig. 7). Thus, our study substantiates that
CaCx cases harbouring integrated and episomal HPV16
are distinct at the molecular level.
Besides miR-181c, our study also revealed a strong
positive correlation between miR-323 expression and
Fig. 5 Correlation between miR-323 and E7 expression among cervical cancers. Linear regression analysis of the correlation between miR-323
expression and E7 mRNA expression in (a) CaCx cases (episomal and integrated; p= 0.471), (b) episomal CaCx cases (p= 0.011), and (c) integrated
CaCx cases (p= 0.711). Lower ΔCT means higher expression
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HPV16 E7 expression among episomal CaCx cases. There
are reports showing miR-323 upregulation in metastatic
squamous cell CaCx cases35 and several studies on pros-
tate cancers36,37, which are suggestive of the potential of
this microRNA in imparting aggressiveness to such can-
cers. We also validated this through cell line based in vitro
analysis as indicated in Fig. 4. This was indicative of
the fact that the viral oncogene E7 could regulate host
miRNA expression, which calls for further studies on
detailed molecular mechanisms. The influence of HPV16
oncoproteins E6 and E7 on miR-203 expression during
proliferation and differentiation has already been estab-
lished14. Therefore, the significant positive correlation
between the expression of miR-203 and E7 in CaCx
subtype harbouring integrated HPV16 also merits atten-
tion and further exploration.
In this study, through the correlation analysis between
the prioritised set of miRNAs and their target genes
(experimentally validated and predicted), we have been
instrumental in identifying functional miRNA-mRNA
relationships as detailed in Table S6. Infact, a large pro-
portion of the non-validated target genes revealed nega-
tive correlations with the respective miRNAs at the level
of expression, suggesting that these could be further
analysed for exploring the regulation of miRNAs and
mRNAs in CaCx pathogenesis.
In summary, employing both microarray-based gene
expression profiling and expression analysis of a priori-
tised set of miRNAs, we have been instrumental in
establishing that CaCx cases harbouring both integrated
and episomal HPV16 genomes are distinct molecular
subtypes. Although the TCGA study on cervical cancers38
has been instrumental in highlighting distinct molecular
phenotypes of HPV-active and HPV-inactive cancers, we
have succeeded in revealing distinct molecular subtypes of
HPV16-positive cervical cancers. Our study further
demonstrated deregulation of miRNA expression in CaCx
cases compared with controls, progressive deregulation
of miRNA expression with increase in severity of cervical
status based on histopathology and HPV infections, and
differential expression of miRNAs in CaCx cases har-
bouring episomal and integrated viral genomes. There-
fore, in consideration with our previous observation of the
loss of miRNA-binding sites in viral regulatory regions
facilitating viral gene expressions in CaCx cases39 and
gain of miRNA binding sites in host regulatory regions40
we conclude that host cellular miRNAs have a role in
CaCx pathogenesis. Thus, our findings highlight that
CaCx cases with episomal and integrated HPV16 are
distinct entities at the molecular level and such findings
are of immense translational value, specifically for
designing targeted therapy of CaCx cases.
Fig. 6 miR-323 expression among various categories of CaCx cell lines. Lower ΔCT means higher expression
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Materials and methods
Samples and subjects
The samples used for this study were nested to an
ongoing natural cohort study. The malignant samples
selected for the study were histopathologically confirmed
invasive squamous cell carcinomas and clinically diag-
nosed as tumour stage III and above as per FIGO classi-
fication. Samples were derived from married subjects
attending a cancer referral hospital (Saroj Gupta Centre
and Research Institute, South 24 Parganas, West Bengal,
India) collected within the period of 1998–2013.
The non-malignant and control samples were derived
from married and non-pregnant women with no previous
history of cervical dysplasia/malignancy undergone for
hysterectomy attending a hospital (Calcutta Medical
College Hospital, Kolkata, West Bengal, India). All such
samples were collected during the period of 2010–2013,
with informed consent approved by the institutional
ethical committee for human experimentation. Details
regarding DNA isolation, HPV screening and determi-
nation of HPV16, physical status of HPV16 genomes, and
viral load are described earlier from our laboratory4,41–44.
Microarray-based gene expression analysis
Global gene expression profiling data reported by Sharma
et al. (GEO database, NCBI Accession No: GSE67522) was
used following reclassification of the CaCx samples based
on the physical status of HPV16 genome, to identify
Fig. 7 Correlation between CKS1B and E7 expression among cervical cancers. Linear regression analysis of the correlation between CKS1B
mRNA expression and E7 mRNA expression in (a) CaCx cases (episomal and integrated; p= 0.839), (b) episomal CaCx cases (p= 0.61), and (c)
integrated CaCx cases (p= 0.03). Lower ΔCT means higher expression
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mechanistic differences between cervical cancers harbour-
ing episomal and integrated HPV16. Thus, differential
expression analysis was performed using different categories
of cervical tissues, i.e., HPV-negative control samples
(n= 11), HPV positive non-malignant samples (n= 11),
episomal CaCx cases (n= 10), and integrated CaCx cases
(n= 10) (Table S8). The analysis pipeline was the same as
reported earlier15.
Expression analysis of some candidate microRNAs
The expression of some prioritised miRNAs (34
miRNAs selected on the basis of frequent alterations
in many cancers, identified through literature survey)
were determined by TaqMan miRNA assays as well as
Power SYBR Green based assays (Supplementary
methods 1 and 2 and Figures S7 and S8, respectively)
employing 25 HPV-negative normal samples, 25
HPV16-positive non-malignant samples, and 62
HPV16-positive CaCx cases (43 episomal and 19 inte-
grated HPV16 genomes). The various categories of
miRNAs analysed, and the assays employed are provided
in Supplementary methods 1–3 and Tables S4, Table S9,
and Table S10.
Target prediction of miRNA
The target human genes corresponding to a subset of
the miRNAs analysed in the study, were predicted based
on three prediction softwares like miRanda, PICTAR,
and TargetScan, considering validated miRNA binding
sites as well.
Validation of miRNA target gene CKS1B by quantitative
real-time PCR
Validation was done considering only CKS1B gene that
appeared as target of the significantly altered miR-181c
recorded among episomal CaCx cases only. This gene was
selected based on the fact it belonged to the significantly
enriched pathway corresponding to the CaCx cases.
Samples used for validation by quantitative real-time
PCR included episomal CaCx cases (n= 43), integrated
CaCx cases (n= 19), HPV-negative controls (n= 25), and
HPV16-positive non-malignant samples (n= 25). The
details of primer sequences of CKS1B and GAPDH,
amplicon size and PCR conditions employed is depicted
in Table S10.
Cell culture and transfection
HPV-negative cell line C33A and HPV16-positive cell
lines Caski and SiHa were cultured in Dulbecco's
Modified Eagle Medium supplemented with 10% fetal
bovine serum, 50 Units/ml of penicillin and 50 µg/ml
of streptomycin at 37 °C and 5% CO2. C33A cells were
transfected using Lipofectamine 2000 reagent according
to manufacturer’s protocol, using 1 µg of plasmid
pcDNA3.1-HPV16 E7 vector generated in our labora-
tory15. The cells were harvested and washed with 1× PBS
(pH 7.4), trypsinized, and collected by centrifugation
at 300 g for 10 min The transfected cells were used
further for RNA isolation. The transfection experiments
were carried out in three sets, each in triplicates and
selected miRNAs expression was carried out in selected
cell lines according to the protocol described earlier.
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